Total Payments
$283,375
2024 Payments
$40,154
Companies
35
Transactions
591
Medicare Patients
2,670
Medicare Billing
$382,795
Payment Breakdown by Category
Other$244,099 (86.1%)
Travel$27,708 (9.8%)
Food & Beverage$8,388 (3.0%)
Consulting$2,875 (1.0%)
Education$305.17 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $239,849 | 198 | 84.6% |
| Travel and Lodging | $27,708 | 121 | 9.8% |
| Food and Beverage | $8,388 | 246 | 3.0% |
| Honoraria | $4,250 | 3 | 1.5% |
| Consulting Fee | $2,875 | 4 | 1.0% |
| Education | $305.17 | 19 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $173,007 | 282 | $0 (2024) |
| Allergan, Inc. | $79,970 | 138 | $0 (2021) |
| Melinta Therapeutics, LLC | $22,020 | 56 | $0 (2023) |
| The Medicines Company | $6,450 | 20 | $0 (2017) |
| Insmed, Inc. | $295.96 | 13 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $249.77 | 15 | $0 (2020) |
| Mallinckrodt Enterprises LLC | $182.90 | 10 | $0 (2019) |
| Theravance Biopharma, Inc. | $148.82 | 9 | $0 (2018) |
| Cumberland Pharmaceuticals, Inc. | $115.51 | 7 | $0 (2019) |
| COMSORT, Inc | $100.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,154 | 52 | ABBVIE INC. ($40,059) |
| 2023 | $28,951 | 49 | ABBVIE INC. ($25,137) |
| 2022 | $73,066 | 128 | ABBVIE INC. ($63,950) |
| 2021 | $45,186 | 82 | AbbVie Inc. ($43,861) |
| 2020 | $8,504 | 28 | Allergan, Inc. ($8,353) |
| 2019 | $41,907 | 108 | Allergan Inc. ($37,368) |
| 2018 | $25,177 | 80 | Allergan Inc. ($20,353) |
| 2017 | $20,431 | 64 | Allergan Inc. ($13,596) |
All Payment Transactions
591 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | ABBVIE INC. | TEFLARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/16/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/11/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Travel and Lodging | In-kind items and services | $413.96 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Travel and Lodging | In-kind items and services | $194.41 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $108.87 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Travel and Lodging | In-kind items and services | $97.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Travel and Lodging | In-kind items and services | $45.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $6.59 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/08/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/03/2024 | ABBVIE INC. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $525.96 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/03/2024 | ABBVIE INC. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $269.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/03/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/02/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $120.30 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/02/2024 | ABBVIE INC. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $85.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/02/2024 | ABBVIE INC. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $35.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/17/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $72.85 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/14/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $22.75 | General |
| Category: Coronary | ||||||
| 08/06/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/30/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/10/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $34.84 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/29/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/29/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/21/2024 | ABBVIE INC. | TEFLARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 497 | 905 | $180,707 | $66,302 |
| 2022 | 10 | 587 | 1,062 | $229,609 | $84,079 |
| 2021 | 11 | 672 | 1,173 | $261,531 | $93,422 |
| 2020 | 12 | 914 | 1,694 | $393,413 | $138,992 |
Total Patients
2,670
Total Services
4,834
Medicare Billing
$382,795
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 131 | 437 | $61,180 | $24,872 | 40.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 147 | 170 | $68,000 | $20,842 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 79 | $15,800 | $6,883 | 43.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 66 | $9,570 | $4,057 | 42.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $10,557 | $3,063 | 29.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 50 | 84 | $6,300 | $2,938 | 46.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 27 | $5,400 | $2,391 | 44.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 15 | $3,900 | $1,255 | 32.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 141 | 152 | $60,800 | $22,100 | 36.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 137 | 414 | $57,960 | $20,907 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 102 | $20,400 | $9,437 | 46.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 114 | $22,800 | $8,556 | 37.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 18 | 52 | $27,300 | $8,029 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 73 | 89 | $12,905 | $5,810 | 45.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $11,339 | $3,317 | 29.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 33 | 33 | $8,580 | $3,260 | 38.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 45 | 63 | $4,725 | $1,739 | 36.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $2,800 | $923.98 | 33.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 154 | 182 | $72,800 | $26,606 | 36.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 150 | 438 | $61,320 | $23,063 | 37.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 68 | 101 | $20,200 | $9,491 | 47.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 17 | 54 | $28,350 | $8,652 | 30.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 93 | $18,600 | $6,918 | 37.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 60 | 75 | $10,875 | $5,038 | 46.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $12,121 | $3,669 | 30.3% |
About Dr. Mark Pierce, MD
Dr. Mark Pierce, MD is a Infectious Disease healthcare provider based in Cookeville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053388561.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Pierce, MD has received a total of $283,375 in payments from pharmaceutical and medical device companies, with $40,154 received in 2024. These payments were reported across 591 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($239,849).
As a Medicare-enrolled provider, Pierce has provided services to 2,670 Medicare beneficiaries, totaling 4,834 services with total Medicare billing of $382,795. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Cookeville, TN
- Active Since 03/02/2006
- Last Updated 05/27/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1053388561
Products in Payments
- DALVANCE (Drug) $221,185
- AVYCAZ (Drug) $18,000
- TEFLARO (Drug) $13,791
- Kimyrsa (Drug) $12,814
- Baxdela (Drug) $4,827
- Orbactiv (Drug) $4,019
- ORBACTIV (Drug) $3,212
- MINOCIN IV (Drug) $3,189
- Arikayce (Drug) $279.72
- ZERBAXA (Drug) $214.66
- ACTHAR (Biological) $182.90
- VIBATIV (Drug) $148.82
- VAC VERAFLO (Device) $93.53
- DIFICID (Drug) $87.89
- Vibativ (Drug) $81.84
- Vabomere (Drug) $74.50
- Veltassa (Drug) $71.37
- NUZYRA (Drug) $66.90
- SOLIRIS (Drug) $58.91
- Xerava (Drug) $53.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.